Three key determinants were considered in the selection process: compatibility with LC-MS/MS technology already available in clinical laboratories, ability to improve the prediction of the established preeclampsia biomarker PlGF, and ability to meet patient stratification requirements as identified by clinical practitioners. The gene discussed is PGF; the disease is preeclampsia.